In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
All content for Rx for Biotech is the property of Podcast Host Chris Leidli and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
How Arvinas is Transforming Cancer and Neuroscience Therapies: An Interview with CBO, Randy Teel, PhD
Rx for Biotech
35 minutes 44 seconds
12 months ago
How Arvinas is Transforming Cancer and Neuroscience Therapies: An Interview with CBO, Randy Teel, PhD
Arvinas is a biotech company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. In this podcast episode, Dr. Randy Teel discusses the company's PROTAC protein degrader technology platform and its pipeline of clinical-stage assets, with a focus on vepdegestrant, the company's lead asset that is being co-developed together with partner Pfizer, for the treatment of women with early and locally advanced or metastatic ER+/HER2- breast cancer.
Rx for Biotech
In this episode of Rx for Biotech podcast, I speak with Philippe Chambon MD, PhD, CEO of EG 427, about how his company's HERMES technology platform could improve on the precision, durability and safety of gene therapy delivery.
EG 427's lead candidate, EG110A, targets neurogenic bladder - a chronic condition linked to spinal cord injury, Parkinson's disease and multiple sclerosis - using a localized gene therapy designed to restore neuronal control with minimal side effects.
